US 12,065,474 B2
Chimeric antigen receptors with mutated CD28 costimulatory domains
Marco L. Davila, Tampa, FL (US)
Assigned to H. Lee Moffitt Cancer Center and Research Institute, Inc., Tampa, FL (US)
Appl. No. 16/629,046
Filed by H. Lee Moffitt Cancer Center and Research Institute, Inc., Tampa, FL (US)
PCT Filed Jul. 6, 2018, PCT No. PCT/US2018/041040
§ 371(c)(1), (2) Date Jan. 7, 2020,
PCT Pub. No. WO2019/010383, PCT Pub. Date Jan. 10, 2019.
Claims priority of provisional application 62/529,919, filed on Jul. 7, 2017.
Prior Publication US 2020/0129554 A1, Apr. 30, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/17 (2015.01); A61K 39/00 (2006.01); A61P 35/02 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C12N 15/62 (2006.01)
CPC C07K 14/7051 (2013.01) [A61K 39/001111 (2018.08); A61P 35/02 (2018.01); C07K 14/70521 (2013.01); C07K 16/2803 (2013.01); C07K 16/2809 (2013.01); C07K 16/2818 (2013.01); C12N 15/62 (2013.01); C07K 2319/33 (2013.01); C12N 2510/00 (2013.01)] 10 Claims
OG exemplary drawing
 
1. A chimeric antigen receptor (CAR) polypeptide, comprising a co-stimulatory signaling region, wherein the co-stimulatory signaling region comprises a mutated form of a cytoplasmic domain of CD28 having at least one null mutation in a YMNM (SEQ ID NO:1) subdomain, and at least one null mutation in a PRRP (SEQ ID NO:2) subdomain but not having a null mutation in a PYAP (SEQ ID NO:3) subdomain.